What is wrong with wanting more evidence? Didn't Dr. Kim have center stage with all of his quotes last year and raise expectations for all investors? He Dwarfed our shares and has diluted four times in a year. Even though the 250 registration is still out there, Wall St. wants to justify their investment here with facts in the form of data and P2 didn't do it. The momentum was ours and he lost it with Roche and waiting for Peer Review. I would like to hear him and his colleagues gives something new besides partnering with ourselves. I had the patience for INCY and it was a good ride and hold here for another, but what I see is blown opportunity to boost our awareness. I have no problem with Wall St. wanting more. They are slowly coming around but would be a lot quicker with data and partnership PR.
He stinks at third party support. Can't seem to hold the one he had. It has crippled the share price and continues to hang over us like a cloud. He has the credentials and education, it is the execution that is lacking. Yes, we have one heck of a pipeline, and yes we have diluted to death in just one year to give us a good looking balance sheet, but we need data and partnerships to really become noticed again. Right now ADXS seems to be the darling the pharma industry is touting, and for good reasons. I compare the two and see both as great plays, but I feel DR. Kim has squandered his opportunity and lost all momentum. Now, it is data and partnerships that will move the needle and get us noticed. We see a clear runway to 2018 and the street sees more dilution on the back of dilution and another RS in the que. As long as that is what he presents to the market we are a long, long way off going it alone. Rah, rah, rah.
I have said this many times here and this is a prime example. We have to have big pharma partners on some of our indications. I am sick of hearing we can go it alone rah, rah, rah. This seems to be the big #$%$ in the armor for Dr. Kim. Won't move the needle here with Geneone, you are right Alex. I really gave him more credit than he deserved in the financial area.
To generate some investment interest in this company. The shareholders can't do it by themselves. Everything I read here just indicates just how lax this management team is in trying to get investors interested. With the tax credit going forward and the Sony contract, the investment world should be taking notice and they're not. I think that is the point of the mirro7 rant, and many of us understand the frustration.
As a side note, I did add today and will hold this level for some time. I do believe Sony has to start getting their investment back sooner rather than later.
Sony is the key and Tokman is Tokman. Why would he consider shareholders at this point in our travels? Although it is up to our customers to announce there is nothing prohibiting MVIS from keeping us informed as to the progress being made on the laser front and the power and size fronts. I have always questioned Tokmans abilities and will never understand his reluctance to provide investors decent information to attract additional or new investment here. I also don't think he gives a dam as we approach the ASM and don't really look for anything we don't already know. Tokman is Tokman.
Well gentlemen, I did my best with the CES up dates as I received reports. I hope you will do the same and give us some of your deep thoughts on what you see and hear at the ASM.
Exactly, those are questions we deserve answers to or at least a better explanation from management. They don't mind asking for more shares for their performance. They should at least give us some insight as to why they deserve those perks with a little guidance on those issues you boys have brought up.